Lexeo Therapeutics, Inc. Retained Earnings
Lexeo Therapeutics, Inc. (LXEO) had Retained Earnings of -$426.20 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$426.20M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$400.33M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$380.13M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$359.21M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$426.20M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$400.33M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | -$380.13M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$359.21M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$338.93M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$312.83M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$280.17M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$254.25M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$224.76M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$224.80M 10-Q · filed 2024-08-12 | -$203.52M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$181.84M 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$167.65M 10-Q · filed 2023-12-11 | |
| 2022-12-31 | -$115.45M 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |